摘要
目的:观察阿昔洛韦治疗儿童传染性单核细胞增多症(IM)的疗效及EBV-DNA定量、异型淋巴细胞计数的差异。方法:将96例IM患儿根据治疗方式不同分为对照组(n=48)和观察组(n=48)。对照组患儿予以利巴韦林注射液治疗;观察组给予阿昔洛韦治疗。比较两组患儿临床疗效,并记录其临床症状改善时间及住院时间、治疗前后的T细胞亚群、心肌酶谱指标变化、治疗后病毒学指标、外周血指标及不良反应发生情况。结果:治疗后,观察组总有效率高于对照组(P<0.05);观察组患儿肝脾肿大恢复时间、淋巴结肿大消退时间、退热时间、咽峡炎消失、异型淋巴细胞<10%时间、住院时间均低于对照组(P<0.05);两组CD4^(+)、CD8^(+)及CD4^(+)/CD8^(+)、LDH、CK、CK-MB水平、EBV-DNA定量阳性率、EBV-CA-IgM阳性率、异型淋巴细胞计数、WBC、淋巴细胞计数组间比较,差异均有统计学意义(P<0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:阿昔洛韦治疗儿童IM疗效优于利巴韦林,前者对患儿免疫功能的调节效果更显著,更有助于减轻心肌损伤,且安全性较高,适宜在临床推广。
Objective:To observe the efficacy of acyclovir in the treatment of infectious mononucleosis(IM) in children and the differences in EBV-DNA quantification and atypical lymphocyte count.Methods:A total of 96 children with IM were selected as subjects and divided into control group(n=48) and observation group(n=48) according to different treatment methods.Control group was given ribavirin injection, while observation group was given acyclovir.The clinical efficacy of the two groups was compared, and the improvement times of clinical symptoms and hospital stay, T cell subsets and myocardial enzyme spectrum indexes before and after treatment, virological indexes and peripheral blood indexes after treatment and occurrence of adverse reactions were recorded.Results:After treatment, the total effective rate in observation group was higher than that in control group(P<0.05).The time of hepatosplenomegaly recovery, time of lymphadenopathy subsidence, time of fever abatement, time of isthmopyra disappearance, time of atypical lymphocyte count<10% and hospital stay in observation group were shorter than those in control group(P<0.05).There were statistical differences in the levels of CD4^(+),CD8^(+)and CD4^(+)/CD8^(+),levels of LDH,CK and CK-MB,positive rate of EBV-DNA quantitation, EBV-CA-IgM positive rate, atypical lymphocyte count, WBC and lymphocyte count between the groups(P<0.05).There was no statistical significance in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Acyclovirhas a better efficacy than ribavirin in the treatment of children with IM,and the former one has a more significantregulation effect on immune function in children, and it is more helpful to reduce myocardial injury and has higher safety, thus it is suitable for clinical promotion.
作者
袁焘
余波
YUAN Tao;YU Bo(Department of Pediatrics,363 Hospital,Chengdu 611730,Sichuan,China)
出处
《川北医学院学报》
CAS
2023年第2期225-228,共4页
Journal of North Sichuan Medical College
